Angle PLC

Parsortix enables CTC molecular characterisation - Seite 2

"In the study we have demonstrated that ANGLE's Parsortix™ system addresses key limitations of other approaches for CTC liquid biopsy through the combination of its sensitivity in isolating circulating cancer cells in blood and the high purity of the harvested cells enabling their direct molecular analysis."

ANGLE Founder and Chief Executive, Andrew Newland, commented:
"This published study further demonstrates that the Parsortix™ system outperforms other approaches for harvesting circulating tumour cells from the blood of cancer patients in the fast emerging liquid biopsy market. The capability to harvest cancer cells with high purity to allow direct molecular analysis of the cells strongly differentiates our system, which should facilitate adoption in clinical practice."

For further information ANGLE:
ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain	[phone]
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee	[phone]
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Kimberly Ha (US)	[phone] [phone]

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.